CR11631A - Paramyxovirus eficaz como antitumoral - Google Patents

Paramyxovirus eficaz como antitumoral

Info

Publication number
CR11631A
CR11631A CR11631A CR11631A CR11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A
Authority
CR
Costa Rica
Prior art keywords
paramyxovirus
human
antitumoral
effective
virus
Prior art date
Application number
CR11631A
Other languages
English (en)
Inventor
Beier Rudolf
Puhler Florian
Original Assignee
Bayer Schering Pharma Ag
Grace Procurements Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Grace Procurements Llc filed Critical Bayer Schering Pharma Ag
Publication of CR11631A publication Critical patent/CR11631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen paramyxovirus del grupo APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, virus Mapueray virus Fer-de-Lance, los cuales pueden ser usados para la produccion de un medicamento para el tratamiento de tumores. El virud tienhe la selectividad para matar celulas diferenciadas tumorales humanas pero no para matar celulas diferenciadas normales humanas o en proliferacion normal humanas con la misma dosis.
CR11631A 2008-02-14 2010-08-13 Paramyxovirus eficaz como antitumoral CR11631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075121 2008-02-14
US2965008P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
CR11631A true CR11631A (es) 2010-10-05

Family

ID=40955326

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11631A CR11631A (es) 2008-02-14 2010-08-13 Paramyxovirus eficaz como antitumoral

Country Status (17)

Country Link
US (1) US20090208495A1 (es)
EP (1) EP2252307A2 (es)
JP (1) JP2011512344A (es)
KR (1) KR20100122482A (es)
CN (1) CN101945660A (es)
AU (1) AU2009214066A1 (es)
BR (1) BRPI0908365A2 (es)
CA (1) CA2715136A1 (es)
CO (1) CO6290694A2 (es)
CR (1) CR11631A (es)
DO (1) DOP2010000251A (es)
EA (1) EA201001266A1 (es)
EC (1) ECSP10010401A (es)
IL (1) IL206860A0 (es)
MX (1) MX2010008942A (es)
WO (1) WO2009101149A2 (es)
ZA (1) ZA201006561B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771540C (en) * 2009-08-21 2019-01-15 Merial Limited Recombinant avian paramyxovirus vaccine and method for making and using thereof
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
EP2579884B1 (en) 2010-06-10 2014-06-04 Intervet International B.V. Anti-tumor composition
AU2013212097B2 (en) * 2012-01-24 2017-01-12 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines
CN106163532B (zh) 2013-09-03 2019-12-31 免疫医疗有限公司 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP2021530501A (ja) * 2018-07-13 2021-11-11 アイカーン スクール オブ メディシン アット マウント サイナイ 癌の治療のためのａｐｍｖ及びその使用
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN115089591B (zh) * 2022-05-21 2024-04-12 复旦大学 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010393A (es) * 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
AU7607900A (en) * 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
CN101875919A (zh) * 2004-11-12 2010-11-03 拜耳先灵医药股份有限公司 重组新城疫病毒

Also Published As

Publication number Publication date
IL206860A0 (en) 2010-12-30
WO2009101149A2 (en) 2009-08-20
WO2009101149A3 (en) 2009-11-05
CA2715136A1 (en) 2009-08-20
CO6290694A2 (es) 2011-06-20
ZA201006561B (en) 2012-02-29
CN101945660A (zh) 2011-01-12
ECSP10010401A (es) 2010-09-30
EP2252307A2 (en) 2010-11-24
EA201001266A1 (ru) 2011-04-29
MX2010008942A (es) 2010-09-07
DOP2010000251A (es) 2010-08-31
BRPI0908365A2 (pt) 2015-08-11
KR20100122482A (ko) 2010-11-22
US20090208495A1 (en) 2009-08-20
AU2009214066A1 (en) 2009-08-20
JP2011512344A (ja) 2011-04-21

Similar Documents

Publication Publication Date Title
CR11631A (es) Paramyxovirus eficaz como antitumoral
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
EA201591401A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
DOP2015000300A (es) Compuestos de pirimidinodiona contra estados cardíacos
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
DOP2014000277A (es) Compuestos y composiciones que modulan la actividad del receptor de factor de crecimiento epidérmico (egfr)
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
SV2017005373A (es) Inhibidores de la proteína quinasa c y métodos de su uso
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112013020041A2 (pt) compostos e métodos para a modulação de quinases, e indicações para os mesmos
EA201591405A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
GT201200164A (es) "nuevos compuestos de espiropiperidina"
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
MX377118B (es) C. novyi para el tratamiento de tumores solidos en humanos.
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)